Q3 25 EPS
$2.80
BEAT +1.49%
Est. $2.76
Q3 25 Revenue
$23.99B
BEAT +1.00%
Est. $23.76B
vs S&P Since Q3 25
+13.7%
BEATING MARKET
JNJ +22.6% vs S&P +8.8%
Market Reaction
Did JNJ Beat Earnings? Q3 2025 Results
Johnson & Johnson posted a clean beat across the board in Q3 2025, reporting adjusted diluted EPS of $2.80 against a consensus of $2.76, a 1.49% beat, while revenue of $23.99 billion edged past estimates by 1.00% and climbed 6.8% year over year. The … Read more Johnson & Johnson posted a clean beat across the board in Q3 2025, reporting adjusted diluted EPS of $2.80 against a consensus of $2.76, a 1.49% beat, while revenue of $23.99 billion edged past estimates by 1.00% and climbed 6.8% year over year. The headline numbers were powered by a pharmaceutical portfolio firing on multiple cylinders: DARZALEX surged 21.7% to $3.67 billion, TREMFYA jumped 41.3% to $1.42 billion, and cell therapy CARVYKTI nearly doubled, rising 83.5% to $524 million, more than offsetting the continued erosion of STELARA to biosimilar competition, which fell 41.3% to $1.57 billion. MedTech contributed $8.43 billion in sales, with Cardiovascular leading at $2.21 billion on 12.6% growth. The quarter's most consequential development was J&J's announcement that it intends to spin off its DePuy Synthes orthopaedics unit within 18 to 24 months, a move designed to sharpen focus on higher-growth segments, a meaningful strategic shift as diversified healthcare giants reposition their portfolios. Management raised full-year 2025 sales guidance to approximately $93.70 billion while reaffirming adjusted EPS guidance of $10.85 at the midpoint.
Key Takeaways
- • DARZALEX growth of 21.7% driven by continued market expansion in multiple myeloma
- • TREMFYA growth of 41.3% driven by new indications and market share gains in immunology
- • CARVYKTI growth of 83.5% as CAR-T cell therapy adoption accelerates in oncology
- • SPRAVATO growth of 61.5% in treatment-resistant depression
- • CAPLYTA contributing $240M from Intra-Cellular Therapies acquisition (April 2025)
- • MedTech Cardiovascular growth of 12.6% driven by electrophysiology, Abiomed and Shockwave
- • Surgical Vision growth of 14.9%
- • Partial offset from STELARA biosimilar erosion (-41.3%) and IMBRUVICA decline (-7.8%)
JNJ YoY Financials
Q3 2025 vs Q3 2024, source: SEC Filings
JNJ Revenue by Segment
With YoY comparisons, source: SEC Filings
JNJ Revenue by Geography
With YoY comparisons, source: SEC Filings
“Johnson & Johnson delivered another strong performance in the third quarter fueled by the depth and strength of our portfolio and significant progress across our pipeline. With a sharpened focus on the six priority areas of Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision, Johnson & Johnson is in a new era of accelerated growth and innovation, with pioneering treatments that will continue to transform lives.”
— Joaquin Duato, Q3 2025 Earnings Press Release
JNJ Earnings Trends
JNJ vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
JNJ EPS Trend
Earnings per share: estimate vs actual
JNJ Revenue Trend
Quarterly revenue: estimate vs actual
JNJ Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 | — | $2.70 | — | $24.06B | +1.89% |
| Q4 25 BEAT FY | $2.46 | $2.46 | +0.00% | $24.56B | — |
| FY Full Year | $10.80 | $10.79 | -0.13% | $94.19B | +0.46% |
| Q3 25 BEAT | $2.76 | $2.80 | +1.49% | $23.99B | +1.00% |
| Q2 25 BEAT | $2.68 | $2.77 | +3.43% | $23.74B | +3.88% |
| Q1 25 BEAT | $2.58 | $2.77 | +7.34% | $21.89B | +1.48% |